1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,053 | 0,065 | 26.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.07. | VIVA BIOTECH (01873): THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 03.07. | VIVA BIOTECH (01873): CLARIFICATION ANNOUNCEMENT | - | HKEx | ||
| 26.06. | VIVA BIOTECH (01873): THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 26.06. | VIVA BIOTECH (01873): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2024 | 1 | HKEx | ||
| 31.05. | VIVA BIOTECH (01873): UPDATE ANNOUNCEMENT ADOPTION OF THE VIVA SHANGHAI PHASE I SHARE OPTION SCHEME AND THE VIVA SHANGHAI PHASE II SHARE OPTION SCHEME; ... | 1 | HKEx | ||
| 26.04. | VIVA BIOTECH (01873): NOTICE OF PUBLICATION OF ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023 OF THE COMPANY (THE "2023 ESG REPORT") | - | HKEx | ||
| 26.04. | VIVA BIOTECH (01873): 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 26.04. | VIVA BIOTECH (01873): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 26.04. | VIVA BIOTECH (01873): NOTIFICATION LETTER AND CHANGE REQUEST FORM TO REGISTERED SHAREHOLDERS | - | HKEx | ||
| 26.04. | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| 26.04. | VIVA BIOTECH (01873): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 26.04. | VIVA BIOTECH (01873): PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
| 26.04. | VIVA BIOTECH (01873): 2023 ANNUAL REPORT | - | HKEx | ||
| 28.03. | Viva Biotech Holdings: Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future | 89 | PR Newswire | HONG KONG, March 28, 2024 /PRNewswire/ --
Highlights of the Annual Results as of December 31, 2023:
Revenue reached RMB2,155.6 million
Gross profit amounted to RMB738.5 million
Adjusted non-IFRS... ► Artikel lesen | |
| 28.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION ... | - | HKEx | ||
| 18.03. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx | ||
| 29.08.23 | Viva Biotech Holdings: Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability | 415 | PR Newswire | Highlights of the Interim Results as of June 30, 2023 :
Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0%
Gross profit amounted to RMB406.0 million, representing... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,292 | +0,12 % | Valneva-Aktie +6%: Das bringt neuen Schwung | Nach einer scharfen Korrektur am Freitag springt die Valneva-Aktie (WKN: A0MVJZ) am Montagmorgen um knapp +6% auf 3,48€. Eine bedeutende Finanzspritze sorgt für neue Impulse. Kann der Biotech-Titel... ► Artikel lesen | |
| NOVONESIS | 57,82 | -0,10 % | Novozymes A/S: The era of biosolutions. Outlook upgraded for 2024 | Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased... ► Artikel lesen | |
| GENMAB | 260,90 | -0,04 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2024 | Company Announcement Net sales of DARZALEX® in the second quarter of 2024 totaled USD 2,878 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,632 | +1,23 % | Arbutus Biopharma Corporation: Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 | WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology... ► Artikel lesen | |
| BEIGENE LTD ADR | 148,00 | -1,33 % | BeiGene, Ltd.: BeiGene eröffnet Flaggschiff-Anlage für Biologika-Herstellung und klinische Forschung und Entwicklung in den USA und setzt die globale Expansion fort, um mehr Patienten auf der ganzen Welt mit Medikamenten zu versorgen | 800-Millionen-Dollar-Investition in New Jersey unterstützt globales Wachstum und Expansion mit technologisch fortschrittlichen Produktionskapazitäten und klinischen Entwicklungsmöglichkeiten für... ► Artikel lesen | |
| MOLECULIN BIOTECH | 3,360 | -11,11 % | Moleculin Biotech, Inc. - S-1, General form for registration of securities | ||
| BIOXCEL THERAPEUTICS | 1,070 | +0,56 % | BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI (dexmedetomidine) Sublingual Film | Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter... ► Artikel lesen | |
| SINO BIOPHARM | 0,320 | -4,36 % | Aktienmarkt: Kurs der Sino Biopharmaceutical-Aktie im Minus (0,33 €) | Der Anteilsschein von Sino Biopharmaceutical notiert heute ein wenig leichter. Das Papier notiert derzeit bei 0,33 Euro. Das Wertpapier von Sino Biopharmaceutical verzeichnet aktuell einen Kursverlust... ► Artikel lesen | |
| VERICEL | 49,000 | +1,66 % | Vericel Corporation: Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer | ||
| SENSEI BIOTHERAPEUTICS | 0,614 | +0,99 % | Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 | - Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast... ► Artikel lesen | |
| ZAI LAB LTD ADR | 17,600 | +1,15 % | Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem | ||
| MUSTGROW BIOLOGICS | 0,486 | +0,62 % | MustGrow Biologics Corp.: MustGrow Accelerates California Sales and Marketing Efforts for TerraSante Biofertility Product | MustGrow to attend annual Strawberry Center Field Day at Cal Poly to promote biofertility product TerraSanteTM to hundreds of strawberry growers, researchers, and farming industry representatives.MustGrow... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,137 | -3,52 % | CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer | Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved in Europe for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC)... ► Artikel lesen | |
| REGENXBIO | 13,400 | +1,52 % | REGENXBIO Inc.: REGENXBIO Announces Expansion of AFFINITY DUCHENNE Trial to Include a New Cohort of Younger Patients | Company to begin enrollment of patients aged 1-3 years
Expects data from younger cohort to be part of pivotal plans and BLA filing for broad label
End-of-Phase II meeting with FDA scheduled for... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 6,200 | +3,33 % | FRX Innovations Inc: Fennec Pharmaceuticals suspended by OSC |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,57 % bei einem Aktienkurs von 0,054 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.
